Cancer Family
Neuroepithelial Neoplasm
CI-CAN-00000287Explore in graph →
Non-malignant811 active trials6 approved drugs154 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000287Explore in graph →
Clinical trials
2,934 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03287063 | Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma | terminated | — | 6 | University of Michigan Rogel Cancer CenterOTHER |
| 1 |
| Jul 1, 2025 |
| clinicaltrials |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | terminated | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g)(OU-SCC-PI-4G) | terminated | Phase 2 | 15 | University of OklahomaOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT01324635 | Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors | terminated | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 40 | Alaunos TherapeuticsINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04544007 | A Phase II Trial of Poly-ICLC for Low-Grade Gliomas(NF111) | terminated | Phase 2 | 3 | University of Alabama at BirminghamOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04469699 | Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma(NOA11) | terminated | Phase 2 | 30 | University Hospital MuensterOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas | terminated | Phase 1 / Phase 2 | 7 | Dawonmedax Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | terminated | Phase 1 | 10 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | terminated | Phase 1 | 134 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma(MAGIC-G1) | terminated | Phase 1 | 4 | Biodexa PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | terminated | Phase 2 | 90 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03717142 | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | terminated | N/A | 4 | Lumicell, Inc.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04552756 | Seizures During Radiotherapy for High-grade Gliomas(SURF-ROGG) | terminated | N/A | 23 | University Hospital Schleswig-HolsteinOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | terminated | Phase 2 | 84 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)(KONQUER) | terminated | Phase 1 | 10 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | terminated | Phase 1 / Phase 2 | 74 | Karyopharm Therapeutics IncINDUSTRY | 2 | Dec 16, 2024 | clinicaltrials |
| NCT01247922 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | terminated | Phase 2 | 4 | OSI PharmaceuticalsINDUSTRY | 3 | Dec 6, 2024 | clinicaltrials |
| NCT04128774 | Function and Composition of Regulatory B Cells in Participants With Glioblastoma(GBMdexaB) | terminated | — | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | terminated | Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | terminated | Phase 2 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04952571 | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) | terminated | Phase 2 | 3 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03363659 | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | terminated | Phase 2 | 15 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers | terminated | Phase 1 | 27 | Guido A. Davidzon, MD, SMOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 184 | CelgeneINDUSTRY | 7 | Jul 26, 2024 | clinicaltrials |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM | terminated | Phase 1 / Phase 2 | 8 | SonALAsense, Inc.INDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 | 20 | CelgeneINDUSTRY | 2 | Jul 5, 2024 | clinicaltrials |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | terminated | Phase 1 | 26 | Basilea PharmaceuticaINDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT04221061 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | terminated | Early Phase 1 | 3 | University of PennsylvaniaOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | terminated | Phase 1 | 14 | Nicholas ButowskiOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | terminated | Phase 1 / Phase 2 | 5 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05074992 | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma(NeAT Glio) | terminated | Phase 2 | 1 | University College, LondonOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04681677 | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab(IORT) | terminated | Phase 2 | 12 | Xoft, Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM | terminated | Phase 1 / Phase 2 | 8 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02386241 | Identification of Genomic Changes in Families Having Multiple Members With Tumors | terminated | — | 4 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | terminated | Phase 1 | 3 | Monteris MedicalINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03927222 | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma(I-ATTAC) | terminated | Phase 2 | 6 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04556929 | Enhanced Detection in Glioma Excision(EDGE) | terminated | N/A | 4 | University of OxfordOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | terminated | Phase 1 | 7 | Providence Health & ServicesOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02905643 | Discerning Pseudoprogression vs True Tumor Growth in GBMs | terminated | — | 1 | Ascension HealthINDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2025source: clinicaltrials